A detailed history of Keybank National Association transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Keybank National Association holds 162,341 shares of BMRN stock, worth $10.7 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
162,341
Previous 405,870 60.0%
Holding current value
$10.7 Million
Previous $33.4 Million 65.85%
% of portfolio
0.04%
Previous 0.14%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$69.02 - $93.84 $16.8 Million - $22.9 Million
-243,529 Reduced 60.0%
162,341 $11.4 Million
Q2 2024

Jul 31, 2024

SELL
$74.43 - $92.22 $11.5 Million - $14.3 Million
-154,609 Reduced 27.59%
405,870 $33.4 Million
Q1 2024

May 14, 2024

SELL
$83.81 - $99.0 $5.07 Million - $5.99 Million
-60,479 Reduced 9.74%
560,479 $49 Million
Q4 2023

Feb 13, 2024

BUY
$76.22 - $98.51 $767,687 - $992,192
10,072 Added 1.65%
620,958 $59.9 Million
Q3 2023

Nov 08, 2023

BUY
$85.07 - $94.48 $1.78 Million - $1.97 Million
20,884 Added 3.54%
610,886 $54.1 Million
Q2 2023

Aug 01, 2023

BUY
$86.68 - $100.3 $2.51 Million - $2.9 Million
28,952 Added 5.16%
590,002 $51.1 Million
Q1 2023

May 10, 2023

BUY
$87.74 - $117.27 $2.46 Million - $3.29 Million
28,014 Added 5.26%
561,050 $54.6 Million
Q4 2022

Jan 31, 2023

BUY
$80.93 - $108.63 $2.73 Million - $3.67 Million
33,769 Added 6.76%
533,036 $55.2 Million
Q3 2022

Oct 27, 2022

BUY
$82.16 - $96.94 $2.38 Million - $2.81 Million
29,027 Added 6.17%
499,267 $42.3 Million
Q2 2022

Aug 08, 2022

BUY
$71.48 - $86.85 $6.39 Million - $7.76 Million
89,340 Added 23.45%
470,240 $39 Million
Q1 2022

Apr 28, 2022

BUY
$74.28 - $92.69 $5.66 Million - $7.06 Million
76,189 Added 25.0%
380,900 $29.4 Million
Q4 2021

Feb 07, 2022

BUY
$71.72 - $91.47 $8.98 Million - $11.5 Million
125,229 Added 69.77%
304,711 $26.9 Million
Q3 2021

Nov 08, 2021

BUY
$74.77 - $85.47 $230,216 - $263,162
3,079 Added 1.75%
179,482 $13.9 Million
Q2 2021

Aug 12, 2021

BUY
$75.51 - $84.79 $1.26 Million - $1.41 Million
16,632 Added 10.41%
176,403 $14.7 Million
Q1 2021

May 07, 2021

BUY
$74.73 - $90.69 $7.05 Million - $8.55 Million
94,281 Added 143.96%
159,771 $12.1 Million
Q4 2020

Feb 09, 2021

BUY
$72.61 - $90.2 $3.89 Million - $4.83 Million
53,541 Added 448.08%
65,490 $5.74 Million
Q3 2020

Oct 29, 2020

BUY
$71.87 - $131.03 $143,811 - $262,191
2,001 Added 20.11%
11,949 $909,000
Q2 2020

Aug 10, 2020

BUY
$79.55 - $124.22 $143,190 - $223,596
1,800 Added 22.09%
9,948 $1.23 Million
Q1 2020

May 13, 2020

SELL
$71.37 - $96.85 $110,480 - $149,923
-1,548 Reduced 15.97%
8,148 $689,000
Q4 2019

Feb 05, 2020

BUY
$64.27 - $86.37 $623,161 - $837,443
9,696 New
9,696 $820,000
Q3 2019

Nov 04, 2019

SELL
$67.4 - $85.11 $253,019 - $319,502
-3,754 Closed
0 $0
Q2 2019

Aug 01, 2019

SELL
$80.35 - $93.9 $215,498 - $251,839
-2,682 Reduced 41.67%
3,754 $322,000
Q1 2019

May 08, 2019

SELL
$84.2 - $98.62 $65,423 - $76,627
-777 Reduced 10.77%
6,436 $572,000
Q4 2018

Jan 30, 2019

BUY
$80.14 - $106.07 $130,868 - $173,212
1,633 Added 29.27%
7,213 $614,000
Q3 2018

Nov 08, 2018

SELL
$93.92 - $105.72 $480,400 - $540,757
-5,115 Reduced 47.83%
5,580 $541,000
Q2 2018

Aug 08, 2018

BUY
$76.01 - $99.03 $441,770 - $575,562
5,812 Added 119.03%
10,695 $1.01 Million
Q1 2018

May 15, 2018

SELL
$77.67 - $92.63 $103,223 - $123,105
-1,329 Reduced 21.39%
4,883 $396,000
Q4 2017

Feb 08, 2018

SELL
$80.76 - $95.13 $128,731 - $151,637
-1,594 Reduced 20.42%
6,212 $554,000
Q3 2017

Nov 02, 2017

BUY
$80.6 - $94.95 $228,581 - $269,278
2,836 Added 57.06%
7,806 $727,000
Q2 2017

May 14, 2018

SELL
N/A
-2,803 Reduced 36.06%
4,970 $451,000
Q1 2017

May 14, 2018

BUY
N/A
1,895 Added 32.24%
7,773 $682,000
Q4 2016

May 14, 2018

BUY
N/A
5,878
5,878 $487,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Keybank National Association Portfolio

Follow Keybank National Association and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

News

Stay updated on Keybank National Association with notifications on news.